Analyst Consensus ?
ConsensusBuy43 ratings
Bullish3479.1%
Neutral920.9%
Bearish00.0%
Abbott Laboratories · ABT · FY2026 Q2 · Calendar Q3 2026
Abbott Q2 2026 Beats on EPS, Raises Guidance as Device Pipeline Accelerates
Abbott's Q2 2026 results mark a clear inflection from the prior quarter. Comparable sales growth accelerated to 4.8% (from 3.7% in Q1), and adjusted EPS of $1.31 beat the $1.28 consensus by 2.3%. Management raised full-year EPS guidance to $5.45–$5.60, reversing Q1's lowered posture. The market responded with an 11.3% abnormal move on 2.4x baseline volume, with continued upward drift since. The thesis now hinges on a second-half launch wave — Libre Duo, Amulet 360, Bolt 2.0, Tactiflex Duo, and new nutrition products — underpinned by Exact Sciences integration and a planned fifth billion-dollar sensor manufacturing facility.
Reported Before market openNYSEHealthcare
$182.16B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.31
Consensus $1.28
EPS surprise
+2.3%
Reported versus consensus
Reported revenue
$12.59B
Consensus $12.52B
Revenue surprise
+0.6%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+10.7%
Event window
SPY move
-0.5%
Same window
Abnormal move
+11.3%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
+9.9%
Up to 20 sessions
ABTSPY benchmark
Ask FN2 about ABT FY2026 Q2
Transcript, numbers and history already loaded
Why did ABT rise 10.7% after beating EPS estimates in FY2026 Q2?What changed in ABT's guidance and outlook in FY2026 Q2?Give me the bull and bear case for ABT after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
From Q1 to Q2 2026: (1) Guidance posture flipped from lowered to raised — full-year EPS raised to $5.45–$5.60. (2) Comparable sales growth accelerated from 3.7% to 4.8%. (3) New pipeline milestones: CE Mark for Libre Duo dual glucose-ketone sensor, FDA submission for Amulet 360 LAA device, and completion of patient enrollment in the coronary IVL pivotal trial. (4) Abbott disclosed plans for a fifth, billion-dollar sensor manufacturing facility to meet future CGM demand. (5) Capex outlook shifted to 'increasing' from 'not mentioned' in Q1.
Guidance delta
Full-year adjusted EPS guidance raised to $5.45–$5.60. Full-year comparable sales growth guidance reaffirmed at 6.5%–7.5%. This reverses the prior quarter's lowered guidance posture, where management had guided more cautiously amid a weak respiratory season.
Key takeaways
- Q2 comparable sales grew 4.8% and adjusted EPS of $1.31 beat both the midpoint of guidance and the $1.28 consensus estimate.
- Full-year EPS guidance raised to $5.45–$5.60; comparable sales growth guidance reaffirmed at 6.5%–7.5%.
- Five major product launches — Libre Duo, Amulet 360, Bolt 2.0, Tactiflex Duo, and new nutrition products — underpin management's expected second-half acceleration.
- Exact Sciences integration is driving cancer-diagnostics growth through Cologuard adoption and care-gap programs.
- Capex outlook increased, including a planned fifth billion-dollar sensor manufacturing facility for CGM demand.
Management priorities
- Launch Libre Duo dual glucose-ketone sensor internationally this fall; seek FDA approval for U.S. launch.
- Commercialize Amulet 360 left atrial appendage closure device by year-end.
- Execute full U.S. market release of Bolt 2.0 PFA catheter and expand Tactiflex Duo rollout.
- Introduce new nutrition products: collagen protein shake, creatine-enhanced formula, and whole-milk infant formula.
- Advance clinical pipeline: balloon-expandable TAVR, leadless pacing, mitral replacement valve, peripheral IVL, and wearable lactate sensor.
Follow ABT with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$104.88Current
$24.01Low
$126.68Average
$158High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 23, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 22, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 22, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 22, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 22, 2026 |
| BTIG | Buy | Buy | Maintain | Oct 22, 2026 |
| Baird | Outperform | Outperform | Maintain | Oct 22, 2026 |
| Rothschild & Co | Buy | Neutral | Upgrade | Oct 2, 2026 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Aug 13, 2026 |
| UBS | Buy | Buy | Maintain | Jul 28, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 17, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 17, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | May 31, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 20, 2026 |
| Stifel | Buy | Buy | Maintain | Apr 17, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Apr 17, 2026 |
| Benchmark | Buy | Buy | Maintain | Apr 17, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 17, 2026 |
| Freedom Broker | Buy | Hold | Upgrade | Jan 29, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Jan 23, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Oct 16, 2025 |
| Mizuho | Neutral | Neutral | Maintain | Jul 18, 2025 |
| Jefferies | Buy | Hold | Upgrade | Jul 18, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 15, 2025 |
| Argus Research | Buy | Buy | Maintain | Jul 28, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Apr 21, 2022 |
| CFRA | Buy | Buy | Maintain | Apr 20, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Jan 27, 2022 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Oct 27, 2021 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jan 28, 2021 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jan 23, 2020 |
| Guggenheim Securities | Neutral | Buy | Downgrade | Jan 2, 2020 |
| Guggenheim | Neutral | Buy | Downgrade | Jan 2, 2020 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 18, 2019 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| William Blair | Outperform | Market Perform | Upgrade | Jan 25, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | Jan 22, 2018 |
| Deutsche Bank | Buy | Buy | Maintain | Jul 21, 2017 |
| Edward Jones | Buy | Hold | Upgrade | Jun 21, 2016 |
| PiperJaffray | Neutral | Overweight | Downgrade | Apr 28, 2016 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Jan 25, 2016 |
| Gabelli & Co. | Buy | Buy | Maintain | May 21, 2013 |
| Bank oferica | Neutral | Neutral | Maintain | Apr 5, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $104.88. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $120 | $103.08 | +14.4% | Oct 23, 2026 |
| Wells Fargo | Analyst unavailable | $120 | $102.51 | +14.4% | Oct 23, 2026 |
| BTIG | Marie Thibault | $125 | $100.57 | +19.2% | Oct 22, 2026 |
| Wells Fargo | Analyst unavailable | $119 | $100.57 | +13.5% | Oct 22, 2026 |
| Robert W. Baird | Analyst unavailable | $123 | $100.57 | +17.3% | Oct 22, 2026 |
| New Street | Analyst unavailable | $120 | $104.6 | +14.4% | Oct 16, 2026 |
| Barclays | Analyst unavailable | $120 | $98.17 | +14.4% | Oct 6, 2026 |
| Redburn Partners | Ed Ridley-Day | $127 | $96.71 | +21.1% | Oct 2, 2026 |
| Wolfe Research | Analyst unavailable | $130 | $110.92 | +24.0% | Aug 13, 2026 |
| UBS | Patrick Wood | $125 | $108.84 | +19.2% | Jul 28, 2026 |
| Benchmark Co. | Analyst unavailable | $120 | $100.67 | +14.4% | Jul 20, 2026 |
| Piper Sandler | Analyst unavailable | $118 | $98.82 | +12.5% | Jul 17, 2026 |
| BTIG | Analyst unavailable | $134 | $98.82 | +27.8% | Jul 16, 2026 |
| Evercore ISI | Vijay Kumar | $112 | $93.64 | +6.8% | Jul 6, 2026 |
| Robert W. Baird | David Rescott | $121 | $90.68 | +15.4% | Jun 30, 2026 |
| Daiwa | Analyst unavailable | $92 | $92.74 | -12.3% | Apr 22, 2026 |
| Barclays | Matt Miksic | $143 | $96.83 | +36.3% | Apr 20, 2026 |
| UBS | Analyst unavailable | $115 | $95.46 | +9.6% | Apr 17, 2026 |
| Piper Sandler | Analyst unavailable | $115 | $95.46 | +9.6% | Apr 17, 2026 |
| Stifel Nicolaus | Analyst unavailable | $120 | $95.46 | +14.4% | Apr 17, 2026 |
| UBS | Danielle Antalffy | $158 | $108.42 | +50.6% | Mar 13, 2026 |
| New Street | Analyst unavailable | $145 | $108.14 | +38.3% | Mar 13, 2026 |
| Barclays | Analyst unavailable | $142 | $109.3 | +35.4% | Feb 2, 2026 |
| Loop Capital Markets | Ilya Zubkov | $120 | $106.09 | +14.4% | Jan 29, 2026 |
| Evercore ISI | Analyst unavailable | $138 | $108.61 | +31.6% | Jan 23, 2026 |
| UBS | Analyst unavailable | $132 | $108.6 | +25.9% | Jan 23, 2026 |
| Mizuho Securities | Anthony Petrone | $125 | $108.6 | +19.2% | Jan 23, 2026 |
| Piper Sandler | Analyst unavailable | $135 | $108.6 | +28.7% | Jan 23, 2026 |
| Bernstein | Analyst unavailable | $125 | $108.6 | +19.2% | Jan 23, 2026 |
| Wells Fargo | Larry Biegelsen | $122 | $108.6 | +16.3% | Jan 23, 2026 |
| Bernstein | Lee Hambright | $154 | $126.18 | +46.8% | Jan 9, 2026 |
| Goldman Sachs | Analyst unavailable | $152 | $126.18 | +44.9% | Jan 9, 2026 |
| Evercore ISI | Analyst unavailable | $144 | $123.97 | +37.3% | Jan 5, 2026 |
| Barclays | Analyst unavailable | $169 | $124.19 | +61.1% | Jan 5, 2026 |
| BTIG | Marie Thibault | $145 | $126.24 | +38.3% | Dec 22, 2025 |
| Tigress Financial | Analyst unavailable | $145 | $128.12 | +38.3% | Nov 21, 2025 |
| Barclays | Analyst unavailable | $162 | $127.63 | +54.5% | Oct 17, 2025 |
| Wells Fargo | Analyst unavailable | $146 | $129.45 | +39.2% | Oct 16, 2025 |
| Goldman Sachs | Analyst unavailable | $157 | $133.94 | +49.7% | Oct 1, 2025 |
| RBC Capital | Shagun Singh | $147 | $131.49 | +40.2% | Jul 15, 2025 |
| RBC Capital | Shagun Singh | $140 | $126.22 | +33.5% | Apr 15, 2025 |
| Bernstein | Lee Hambright | $135 | $114.25 | +28.7% | Jan 8, 2025 |
| Piper Sandler | Adam Maeder | $133 | $117.82 | +26.8% | Oct 17, 2024 |
| Bernstein | Lee Hambright | $138 | $117.82 | +31.6% | Oct 17, 2024 |
| Jefferies | Matthew Taylor | $125 | $117.82 | +19.2% | Oct 16, 2024 |
| Evercore ISI | Vijay Kumar | $128 | $117.82 | +22.0% | Oct 16, 2024 |
| BTIG | Marie Thibault | $139 | $117.82 | +32.5% | Oct 16, 2024 |
| Oppenheimer | Suraj Kalia | $130 | $114.3 | +24.0% | Oct 8, 2024 |
| RBC Capital | Shagun Singh | $130 | $113.36 | +24.0% | Oct 8, 2024 |
| Roth Capital | Scott Fortune | $24.01 | $54.49 | -77.1% | Sep 19, 2024 |
| Piper Sandler | Adam Maeder | $131 | $114.88 | +24.9% | Sep 19, 2024 |
| Jefferies | Matthew Taylor | $120 | $112.22 | +14.4% | Aug 27, 2024 |
| Citigroup | Joanne Wuensch | $127 | $111.39 | +21.1% | Aug 22, 2024 |
| Citigroup | Joanna Wiensch | $119 | $104.68 | +13.5% | Jul 18, 2024 |
| Evercore ISI | Vijay Kumar | $120 | $103.2 | +14.4% | Jul 2, 2024 |
| BTIG | Marie Thibault | $135 | $102.99 | +28.7% | Jun 3, 2024 |
| Goldman Sachs | David Roman | $121 | $100.73 | +15.4% | May 30, 2024 |
| Barclays | Matt Miksic | $140 | $107.07 | +33.5% | Apr 22, 2024 |
| Bernstein | Lee Hambright | $133 | $105.27 | +26.8% | Apr 18, 2024 |
| RBC Capital | Shagun Singh | $125 | $105.9 | +19.2% | Apr 18, 2024 |
| Morgan Stanley | Analyst unavailable | $133 | $111.37 | +26.8% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $125 | $107.51 | +19.2% | Dec 12, 2022 |
| RBC Capital | Shagun Singh | $132 | $109.78 | +25.9% | Aug 3, 2022 |
| UBS | Analyst unavailable | $128 | $109.09 | +22.0% | Jul 27, 2022 |
| Citigroup | Analyst unavailable | $123 | $108.23 | +17.3% | Jul 21, 2022 |
| BTIG | Analyst unavailable | $126 | $108.36 | +20.1% | Jul 18, 2022 |
| Stifel Nicolaus | Analyst unavailable | $126 | $108.43 | +20.1% | Jul 18, 2022 |
| Raymond James | Analyst unavailable | $117 | $105.71 | +11.6% | Jul 15, 2022 |
| BTIG | Marie Thibault | $130 | $109.45 | +24.0% | Jun 27, 2022 |
| Raymond James | Jayson Bedford | $135 | $119.64 | +28.7% | Apr 25, 2022 |
| RBC Capital | Analyst unavailable | $143 | $122.64 | +36.3% | Apr 21, 2022 |
| BTIG | Marie Thibault | $140 | $123.8 | +33.5% | Apr 21, 2022 |
| New Street | Analyst unavailable | $117.49 | $123.41 | +12.0% | Apr 20, 2022 |
| Wells Fargo | Larry Biegelsen | $150 | $120.04 | +43.0% | Apr 11, 2022 |
| Bank of America Securities | Travis Steed | $140 | $120.97 | +33.5% | Mar 3, 2022 |
| Morgan Stanley | Cecilia Furlong | $151 | $122.41 | +44.0% | Feb 26, 2022 |
| Raymond James | Jayson Bedford | $143 | $129.71 | +36.3% | Feb 6, 2022 |
| Citigroup | Joanne Wuensch | $154 | $135.08 | +46.8% | Dec 15, 2021 |
| Jefferies | Raj Denhoy | $145 | $124.61 | +38.3% | Oct 21, 2021 |
| Stifel Nicolaus | Rick Wise | $130 | $117.38 | +24.0% | Jul 22, 2021 |
| Goldman Sachs | Amit Hazan | $120 | $104.61 | +14.4% | Jun 1, 2021 |
| Evercore ISI | Vijay Kumar | $136 | $121.24 | +29.7% | Apr 21, 2021 |
Track every rating change on ABT the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAbbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools.…
Historical context
All ABT earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
Latest beats and misses
Who reports nextBeat on EPS
- CDNSFY2026 Q3 · October 26, 2026+2.9% EPS+1.8% move
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the ABT recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-17T03:02:55.650105+00:00
- FN2 earnings calendar · 2026-07-28T01:23:15.070317+00:00
- Polygon adjusted daily market bars · 2026-07-28T15:04:59.801032+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T15:04:59.796981+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-07-28. For educational purposes only; not investment advice.